Lightnews — Scholar-powered news

Reposted by Promita Ghosh (she/her)

amitava banerjee @amitava-immuno.bsky.social · 29d

Authoritative review from The one and only @ghoshonthemove.bsky.social ☺️on her doctoral work on NSCLC 🫁 @mcgillgci.bsky.social

portlandpress.com/biochemsoctr...

Need to stay tuned to see if these mutations can generate targetable neoantigens in tricky low-TMB cancers

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression

The MET receptor tyrosine kinase is a pivotal regulator of cellular survival, motility, and proliferation. Mutations leading to skipping of exon 14 (METΔex14) within the juxtamembrane domain of MET im...

portlandpress.com

1 1

Promita Ghosh (she/her) @ghoshonthemove.bsky.social · 29d

Why does MET exon 14 skipping matter? It is more than a mere oncogenic mutation!😱🫁

Hot off the @biochemsoc.bsky.social press where we discuss met exon 14 and beyond
@mcgillgci.bsky.social

portlandpress.com/biochemsoctr...

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression

The MET receptor tyrosine kinase is a pivotal regulator of cellular survival, motility, and proliferation. Mutations leading to skipping of exon 14 (METΔex14) within the juxtamembrane domain of MET im...

portlandpress.com

1 3

Reposted by Promita Ghosh (she/her)

amitava banerjee @amitava-immuno.bsky.social · Jul 25

Got new #TCR-pMHC data to send our way into BATCAVE? Wanna try BATMAN to predict targets of your #TCR? We would love to hear from you!

💽Database+codes: github.com/meyer-lab-cs...

💻BATMAN software + tutorials: github.com/meyer-lab-cs...

🦇Lets decode TCR-pMHC logic, one mutation at a time🦇

7 10

Reposted by Promita Ghosh (she/her)

Soragni:Lab @alice.soragnilab.com · Jun 3

Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies
www.nature.com/articles/s41...

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer

Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

www.nature.com

1 14 35

Reposted by Promita Ghosh (she/her)

Cell Chemical Biology @cp-cellchembiol.bsky.social · Apr 18

Streptomycin Targets Tumor-Initiating Cells by Disrupting the Oxidative Phosphorylation (OXPHOS) Pathway by Hélène Guillorit, @mariaduca-cnrs.bsky.social, Françoise Macari, Alexandre David et al at @cnrs.fr @inserm.fr http://dlvr.it/TKDrwY

2 5

Reposted by Promita Ghosh (she/her)

Nature @nature.com · Apr 18

Nature research paper: Generation of human adult hepatocyte organoids with metabolic functions

https://go.nature.com/43WXrX7

Generation of human adult hepatocyte organoids with metabolic functions - Nature

The combined activation of Wnt and STAT3 signalling enables long-term self-renewal of human hepatocyte organoids, maintaining hepatic identity, supporting gene editing and offering therapeutic potential for liver disease through enhanced functionality, structure and metabolic competency.

go.nature.com

1 4 24

Reposted by Promita Ghosh (she/her)

Science Magazine @science.org · Apr 18

Can blocking “jumping genes” treat diseases and aging?

The first clinical trials are testing inhibitors of transposons, #DNA sequences that hop around the genome on their own. scim.ag/4cHvdC4

Could blocking ‘jumping genes’ help fight disease and aging?

The first clinical trials are testing inhibitors of transposons, DNA sequences that hop around the genome on their own

scim.ag

11 47